Supernus Pharmaceuticals, Inc. (SUPN)

Over the past six months, Supernus Pharmaceuticals' stock price has fluctuated between $29.16 and $59.68. Key events include Q1 2026 financial results with a revenue increase but missed EPS estimates, record revenues for Q4 and full-year 2025, ONAPGO supply constraints due to high demand, insider selling of shares, and the acquisition of Sage Therapeutics, which added ZURZUVAE to the portfolio. New patient initiations for ONAPGO resumed in February 2026, and Q1 2026 net sales for ONAPGO were $8.4 million.

Specific details regarding the demand seasonality for Supernus Pharmaceuticals' individual products and services are not publicly available. The company's focus on chronic CNS diseases suggests that demand for its treatments might be relatively stable throughout the year.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for central nervous system diseases, specializing in neurological and psychiatric disorders. Its portfolio includes treatments for epilepsy, migraine, ADHD, Parkinson's Disease, cervical dystonia, chronic sialorrhea, and postpartum depression. Major products include Trokendi XR, Oxtellar XR, Qelbree, GOCOVRI, APOKYN, XADAGO, MYOBLOC, ZURZUVAE, and ONAPGO. The company also has a pipeline of CNS product candidates under development.

Supernus Pharmaceuticals, Inc. is headquartered in Rockville, Maryland, and primarily focuses on developing and commercializing its products in the United States. While its operations are largely domestic, its shareholder base has an international presence, with a majority from the United States and smaller percentages from countries like Australia and the United Kingdom.

In the past year, Supernus Pharmaceuticals has maintained a positive brand reputation, driven by its focus on CNS therapies and product performance. Key events affecting its reputation include the strong performance of core therapies, the acquisition of Sage Therapeutics, temporary ONAPGO supply constraints, and Q1 2026 earnings miss. The company's proactive communication and efforts to resolve the supply issue aimed to mitigate negative impact.

The ownership of Supernus Pharmaceuticals, Inc. is predominantly held by institutional investors. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Armistice Capital LLC, Dimensional Fund Advisors L.P., Millennium Management LLC, Point72 Asset Management, L.P., State Street Corp, Renaissance Technologies LLC, and Geode Capital Management, L.L.C. CEO Jack A. Khattar holds about 1.6% of outstanding shares.